biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.…
biote: 3 Key Takeaways for Long-Term Investors
biote (NASDAQ: BTMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 223 employees.
The shares were at 0.8147 USD on 20 November 2026, down 69.9% over 52 weeks. Its 52-week range is 0.8100 USD to 2.900 USD, and it trades at the bottom of that range.
Its market capitalisation is 26.28M USD.
biote reports return on equity of -46.2%, an operating margin of 8.3% and revenue down 9.6% year over year.
Its debt exceeds its cash by 118.97M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 2.224 USD is 173.0% above the current price. The next earnings report is expected on 10 March 2027.